Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 9/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.67 |
| ▸ | ALPI | P09923 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | XIAP | P98170 | 1/20 | 0.67 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.62 |
| ▸ | NOS3 | P29474 | 3/20 | 0.60 |
| ▸ | NOS1 | P29475 | 3/20 | 0.60 |
| ▸ | NOS2 | P35228 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485683 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29351918 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL6371428 | 1.00 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL15656470 | 0.95 | SLC7A5 (0.76) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2314258 | 0.93 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL366883 | 0.89 | SLC7A5 (0.85) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL14945063 | 0.86 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31688862 | 0.86 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL25451922 | 0.86 | NOS1 (0.49) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31369893 | 0.86 | SLC7A5 (0.67) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024030977-A2 | NOVEL MELANOCORTIN ANALOGS | SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| CN-111187338-A | Modulation of complement activity | RA制药公司 | 2020-05-22 | — | — | CN | claimed |
| EP-3628680-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2020-04-01 | — | — | EP | claimed |
| US-10208089-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | claimed |
| US-20180371019-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-12-27 | — | — | US | claimed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | claimed |
| EP-3154561-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| CN-106456701-A | Modulation of complement activity | RA制药公司 | 2017-02-22 | — | — | CN | claimed |
| WO-2015191951-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| US-20150166606-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | claimed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | claimed |
| EP-4747882-A1 | DATA STORAGE USING PROTEINS | The Hong Kong Polytechnic University (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4540267-B1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | UCB HOLDINGS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4218790-B1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MARIANA ONCOLOGY INC (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025122615-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MARIANA ONCOLOGY INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4565258-A2 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | Sightstream Biotherapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-115920000-B | Modulators of complement activity | RA制药公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-20250090624-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12239684-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4028126-B1 | TREATMENT OF A NEUROLOGICAL DISEASE WITH COMPLEMENT INHIBITORS | RA PHARMACEUTICALS INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250049970-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250034210-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250032574-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | UCB HOLDINGS, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2025015598-A1 | DATA STORAGE USING PROTEINS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2025-01-23 | — | — | WO | disclosed |
| US-20250011368-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-01-09 | — | — | US | disclosed |
| CN-119236050-A | Modulation of complement activity | RA制药公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2024259115-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024259147-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024259132-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| CN-118648607-A | Application of 3- (4-hydroxyphenyl) -2-methylaminopropionic acid as phytotoxicity relieving agent | 南京农业大学 | 2024-09-17 | — | — | CN | disclosed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | disclosed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| CN-111187338-B | Modulation of complement activity | RA制药公司 | 2024-08-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-20240182526-A1 | COMPOSITIONS AND METHODS FOR MODULTING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIV SOUTHERN CALIFORNIA (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240156896-A1 | Modulators of Complement Activity | UCB HOLDINGS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-11965040-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3980047-B1 | INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | RA PHARMACEUTICALS INC (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024030950-A2 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024030977-A2 | NOVEL MELANOCORTIN ANALOGS | SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-11752190-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11723949-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| EP-4223317-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4218790-A1 | MODULATORS OF COMPLEMENT ACTIVITY | Ra Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | disclosed |
| US-11707503-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-115920000-A | Modulators of complement activity | RA制药公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3685847-B1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11535650-B1 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220370548-A1 | NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | UCB HOLDINGS, INC. | 2022-11-24 | — | — | US | disclosed |
| WO-2022212513-A1 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220296621-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2022-09-22 | — | — | US | disclosed |
| WO-2022177635-A2 | COMPOSITIONS AND METHODS FOR MICROBIAL DISEASE TREATMENT | RA PHARMACEUTICALS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220257697-A1 | INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | UCB HOLDINGS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-108697759-B | Modulators of complement activity | RA制药公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20220233632-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2022-07-28 | — | — | US | disclosed |
| EP-4028126-A1 | NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | RA Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220211799-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-20220160820-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-20220133841-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | RA PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
| CN-114423445-A | Treatment of neurological diseases using complement inhibitors | RA制药公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3988110-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3980047-A1 | INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | RA Pharmaceuticals, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| EP-3973994-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3958842-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3250230-B9 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113966224-A | Treatment of inflammatory diseases with complement inhibitors | RA制药公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |
| EP-3934675-A2 | ZILUCOPLAN AS DEEP TISSUE PENETRATING C5 INHIBITOR | RA Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113786495-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2021-12-14 | — | — | CN | disclosed |
| CN-113710230-A | Compositions and methods for modulating complement activity | RA制药公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11180481-B2 | Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction | NEW YORK UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3250230-B1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113543796-A | Zilucoprol as a deep tissue penetration C5 inhibitor | RA制药公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2021-10-07 | — | — | US | disclosed |
| CN-106573073-B | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2021-09-28 | — | — | CN | disclosed |
| US-11123399-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210283212-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2021-09-09 | — | — | US | disclosed |
| EP-3628680-B1 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2021-09-08 | — | — | EP | disclosed |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ZEALAND PHARMA A/S (DK) | 2021-09-07 | — | — | US | disclosed |
| US-20210246167-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2021-08-12 | — | — | US | disclosed |
| CN-113226368-A | Neurological disease treatment with zilucoprol | RA制药公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11033525-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-11014965-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210090688-A1 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-03-25 | — | — | US | disclosed |
| US-10954287-B2 | Ras binding peptides and methods of use | RA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2021050885-A1 | NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | RA PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20210077572-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10918691-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20210000927-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020247607-A1 | INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | RA PHARMACEUTICALS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10835574-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2020219822-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-3720463-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20200297745-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2020-09-24 | — | — | US | disclosed |
| CN-111683672-A | Modulators of complement activity | RA制药公司 | 2020-09-18 | — | — | CN | disclosed |
| WO-2020185541-A2 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| EP-3685847-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10709722-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200216501-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2020-07-09 | — | — | US | disclosed |
| CN-111187338-A | Modulation of complement activity | RA制药公司 | 2020-05-22 | — | — | CN | disclosed |
| US-20200155639-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200123202-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2020-04-23 | — | — | US | disclosed |
| EP-3628680-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10588936-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3389692-B1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10562934-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200038477-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2020-02-06 | — | — | US | disclosed |
| CN-106456701-B | Modulation of complement activity | RA制药公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-3551210-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190307835-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2850095-B1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10435438-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190275064-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | TRUSTEES OF TUFTS COLLEGE | 2019-09-12 | — | — | US | disclosed |
| EP-3154561-B1 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-110087668-A | The regulator of complement activity | RA制药公司 | 2019-08-02 | — | — | CN | disclosed |
| US-10328115-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2019112984-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-10272132-B2 | Peptide and peptidomimetic inhibitors | RA PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190119328-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20190119358-A1 | RAS BINDING PEPTIDES AND METHODS OF USE | RA PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10245248-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3442991-A1 | RAS BINDING PEPTIDES AND METHODS OF USE | RA Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10208089-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180371019-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-20180369322-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-10117887-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3389692-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-10106579-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| CN-108697759-A | modulators of complement activity | RA制药公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20180256672-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180214579-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193408-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9999650-B2 | Peptide and peptidomimetic inhibitors | RA PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| WO-2018106859-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9937222-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-9925277-B2 | Polynucleotide compositions containing amino acids | MODERNATX, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180021402-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-01-25 | — | — | US | disclosed |
| EP-3250230-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-3251674-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BioCryst Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170319609-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2017-11-09 | — | — | US | disclosed |
| WO-2017181061-A1 | RAS BINDING PEPTIDES AND METHODS OF USE | RA PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9737556-B2 | FAP-activated therapeutic agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170189470-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | disclosed |
| WO-2017105939-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170128476-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2017-05-11 | — | — | US | disclosed |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9644004-B2 | Peptide and peptidomimetic inhibitors | RA PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170119901-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2017-05-04 | — | — | US | disclosed |
| EP-3154561-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3154594-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Trustees Of Tufts College (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| CN-106456701-A | Modulation of complement activity | RA制药公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170037033-A1 | OXOPIPERAZINE HELIX MIMETICS AS INHIBITORS OF THE p53-MDM2 INTERACTION | NEW YORK UNIVERSITY (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160243259-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | disclosed |
| WO-2016123371-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-3043826-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | Moderna Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160083430-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9238676-B2 | Peptide and peptidomimetic inhibitors | RA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| WO-2015192123-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015192124-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015191951-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-9201079-B2 | Methods for quantifying vitamin D metabolites by mass spectrometry | GEORGETOWN UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2919785-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | Biocryst Pharmaceuticals, Inc. (US) | 2015-09-23 | — | — | EP | disclosed |
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150166606-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| EP-2850095-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA Pharmaceuticals, Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838535-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | Biocryst Pharmaceuticals, Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8877908-B2 | Stimulus-responsive apta chelamers | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140296147-A1 | METHODS OF TREATING OR PREVENTING BLOOD LOSS DURING SURGERY USING THE SERINE PROTEASE INHIBITOR MDCO-2010 | MEDICINES CO (US) | 2014-10-02 | — | — | US | disclosed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | disclosed |
| WO-2014078778-A2 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140080140-A1 | SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS | THE INSTITUTE FOR ETHNOMEDICINE | 2014-03-20 | — | — | US | disclosed |
| WO-2013172954-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | RA PHARMACEUTICALS, INC (US) | 2013-11-21 | — | — | WO | disclosed |
| US-8569313-B2 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| WO-2013158746-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| EP-2054380-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | MEDICINES CO LEIPZIG GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8513461-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20130165510-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-06-27 | — | — | US | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013052736-A2 | METHODS OF TREATING OR PREVENTING BLOOD LOSS DURING SURGERY USING THE SERINE PROTEASE INHIBITOR MDCO-2010 | THE MEDICINES COMPANY (US) | 2013-04-11 | — | — | WO | disclosed |
| US-8410310-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120244627-A1 | Methods for Quantifying Vitamin D Metabolites by Mass Spectrometry | GEORGETOWN UNIVERSITY (US) | 2012-09-27 | — | — | US | disclosed |
| EP-2502906-A2 | Trypsin-like serine protease inhibitors, their preparation and use | The Medicines Company (Leipzig) GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225913-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | The Medicine Company (Leipzig) GmbH (DE) | 2012-09-06 | — | — | US | disclosed |
| US-8207378-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2132174-B1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MEDICINES CO LEIPZIG GMBH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245173-A1 | Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction | TRUSTEES OF TUFTS COLLEGE | 2011-10-06 | — | — | US | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
| EP-1860441-B1 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | INST ETHNOMEDICINE (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110190483-A1 | Stimulus-Responsive Apta Chelamers | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011056415-A1 | METHODS FOR QUANTIFYING VITAMIN D METABOLITES BY MASS SPECTROMETRY | GEORGETOWN UNIVERSITY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-7901895-B2 | Screening environmental samples such as food, water for beta-N-methylamino-L-alanine (BMAA) associated with risk of nervous system disorders such as dementia, amyotrophic lateral sclerosis | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-7763734-B2 | Synthesis, structure and use of bisoxazolidines for asymmetric catalysis and synthesis | GEORGETOWN UNIVERSITY (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100184706-A1 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE | 2010-07-22 | — | — | US | disclosed |
| US-20100105753-A1 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105629-A1 | N-Substituted Peptidomimetic Inhibitors of Dipeptidylpeptidase IV | TRUSTEES OF TUFTS COLLEGE | 2010-04-29 | — | — | US | disclosed |
| CN-100595588-C | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | NAT TROPICAL BOTAN GARDEN | 2010-03-24 | — | — | CN | disclosed |
| US-7670783-B2 | Screening for neurotoxic amino acid associated with neurological disorders | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2010-03-02 | — | — | US | disclosed |
| US-20100022781-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| WO-2010006238-A2 | STIMULUS-RESPONSIVE APTA-CHELAMERS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-2139337-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | Trustees Of Tufts College (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2132174-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | The Medicines Company (Leipzig) GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009149148-A2 | LONG-ACTING GLP-1 DERIVATIVES, AND METHODS OF TREATING CARDIAC DYSFUNCTION | TRUSTEES OF TUFTS COLLEGE (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2009006473-A2 | PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008107176-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1664793-B9 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | INST ETHNOMEDICINE (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070292893-A1 | Screening for neurotoxic amino acid associated with neurological disorders | NATIONAL TROPICAL BOTANICAL GARDENS | 2007-12-20 | — | — | US | disclosed |
| EP-1860441-A2 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | The Institute for Ethnomedicine (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
| EP-1664793-B1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | INST ETHNOMEDICINE (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070254315-A1 | SCREENING FOR NEUROTOXIC AMINO ACID ASSOCIATED WITH NEUROLOGICAL DISORDERS | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2007-11-01 | — | — | US | disclosed |
| US-7256002-B2 | Screening for neurotoxic amino acid associated with neurological disorders | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2007-08-14 | — | — | US | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| CN-1860369-A | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | NAT TROPICAL BOTAN GARDEN (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1664793-A1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | Institute For Ethnomedicine (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005019830-A1 | NEUROTOXIC AMINO ACID OR NEUROTOXIC DERIVATIVE THEREOF ASSOCIATED WITH NEUROLOGICAL DISORDERS | INSTITUTE FOR ETHNOMEDICINE (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050042686-A1 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | NATIONAL TROPICAL BOTANICAL GARDEN | 2005-02-24 | — | — | US | disclosed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-5518735-A | ANTICOAGULANTS ADMINISTERED BY MOUTH | PENTAPHARM AG (CH) | 1996-05-21 | — | — | US | disclosed |
| EP-0511347-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | Pentapharm A.G. (CH) | 1992-11-04 | — | — | EP | disclosed |
| WO-1992008709-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | PENTAPHARM AG (CH) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008709-A1 | META-SUBSTITUTED PHENYL ALANINE DERIVATIVES | PENTAPHARM AG (CH) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC7A5 1512/4885PTGS1 1087/4885ALPI 341/4885 |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | SLC7A5 3906/4885PTGS1 388/4885ALPI 3402/4885 |
| US-11707503-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-11111273-B2 | Cyclic peptides multimers targeting alpha-4-beta-7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885PTGS1 4496/4885ALPI 3773/4885 |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC7A5 1560/4885PTGS1 823/4885ALPI 496/4885 |
| US-20110245173-A1 | Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction | GLP1R, GIPR, DPP9 | SLC7A5 2433/4885PTGS1 669/4885ALPI 526/4885 |
| US-20180021402-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | SLC7A5 50/4885PTGS1 4600/4885ALPI 4058/4885 |
| US-20220370548-A1 | NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | C9, SMN1; SMN2, CFB | SLC7A5 3998/4885PTGS1 2034/4885ALPI 4837/4885 |
| US-10588936-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-20220160820-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C5, C1QBP, C9 | SLC7A5 4577/4885PTGS1 1938/4885ALPI 2439/4885 |
| US-20100105753-A1 | Inhibitors of Fibroblast Activation Protein, and Methods of Use Thereof | FAP, FIBP, DNPEP | SLC7A5 3946/4885PTGS1 2606/4885ALPI 313/4885 |
| US-20120244627-A1 | Methods for Quantifying Vitamin D Metabolites by Mass Spectrometry | CYP24A1, CYP2R1, VDR | SLC7A5 900/4885PTGS1 3541/4885ALPI 933/4885 |
| US-20100184706-A1 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | FAP, DPYD, TYMP | SLC7A5 2650/4885PTGS1 1648/4885ALPI 151/4885 |
| US-11033525-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC7A5 1512/4885PTGS1 1087/4885ALPI 341/4885 |
| US-11014965-B2 | Modulation of complement activity | C5, C3AR1, CFH | SLC7A5 4760/4885PTGS1 1733/4885ALPI 4765/4885 |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | SLC7A5 1512/4885PTGS1 1087/4885ALPI 341/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | SLC7A5 1512/4885PTGS1 1087/4885ALPI 341/4885 |
| US-20210246167-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | SLC7A5 4760/4885PTGS1 1733/4885ALPI 4765/4885 |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | SLC7A5 1512/4885PTGS1 1087/4885ALPI 341/4885 |
| US-11123399-B2 | Modulators of complement activity | C1QBP, C5, C3AR1 | SLC7A5 4148/4885PTGS1 1832/4885ALPI 4742/4885 |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | SLC7A5 4410/4885PTGS1 84/4885ALPI 1437/4885 |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MMP7, DNPEP, METAP1 | SLC7A5 95/4885PTGS1 1381/4885ALPI 1829/4885 |
| US-20220211799-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT ACTIVITY | C5, C9, C1QBP | SLC7A5 2940/4885PTGS1 1074/4885ALPI 1271/4885 |
| US-20210283212-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-20250032574-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | ACHE, C5, BCHE | SLC7A5 4658/4885PTGS1 1771/4885ALPI 4121/4885 |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | SLC7A5 4195/4885PTGS1 605/4885ALPI 673/4885 |
| US-20180256672-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | KLKB1, KLK1, KLK5 | SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885 |
| US-20250186541-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | DLK1, DBNL, PDLIM5 | SLC7A5 1303/4885PTGS1 4817/4885ALPI 4319/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2076/4885PTGS1 4545/4885ALPI 3864/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | SLC7A5 843/4885PTGS1 4251/4885ALPI 4507/4885 |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | SLC7A5 4195/4885PTGS1 605/4885ALPI 673/4885 |
| US-20190119328-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | SLC7A5 4760/4885PTGS1 1733/4885ALPI 4765/4885 |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | SLC7A5 4760/4885PTGS1 1733/4885ALPI 4765/4885 |
| US-20170189470-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | KLKB1, KLK1, KLK5 | SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885 |
| US-20170037033-A1 | OXOPIPERAZINE HELIX MIMETICS AS INHIBITORS OF THE p53-MDM2 INTERACTION | TP53, MDM2, TP53BP1 | SLC7A5 3456/4885PTGS1 2303/4885ALPI 2878/4885 |
| US-20150166606-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | KLKB1, KLK1, KLK5 | SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885 |
| US-10918691-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-20190307835-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-20120225913-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | SERPINE1, TFPI, SPINT2 | SLC7A5 3961/4885PTGS1 596/4885ALPI 953/4885 |
| US-10328115-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | SLC7A5 4419/4885PTGS1 1910/4885ALPI 4790/4885 |
| US-10272132-B2 | Peptide and peptidomimetic inhibitors | KLKB1, KLK1, KLK5 | SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | SLC7A5 4712/4885PTGS1 1407/4885ALPI 2075/4885 |
| US-20160083430-A1 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS | KLKB1, KLK1, KLK5 | SLC7A5 2730/4885PTGS1 1388/4885ALPI 3771/4885 |
| US-20200297745-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | FAP, FIBP, GOT1 | SLC7A5 1560/4885PTGS1 823/4885ALPI 496/4885 |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | SLC7A5 433/4885PTGS1 2448/4885ALPI 68/4885 |
| US-20110190483-A1 | Stimulus-Responsive Apta Chelamers | CNBP, CREB1, ATF4 | SLC7A5 4319/4885PTGS1 4418/4885ALPI 3804/4885 |
| US-11723949-B2 | Modulators of complement activity | C1QBP, C5, C3AR1 | SLC7A5 4148/4885PTGS1 1832/4885ALPI 4742/4885 |
| US-11180481-B2 | Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction | TP53, MDM2, TP53BP1 | SLC7A5 3584/4885PTGS1 1905/4885ALPI 2419/4885 |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | ASGR1, GPR119, LDLR | SLC7A5 264/4885PTGS1 4481/4885ALPI 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.